WEBULL
WebtradeDownload

HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?

Simply Wall St · 2d ago

HBM Holdings (SEHK:2142) has drawn fresh attention after Harbour BioMed announced two company level developments. Investors are weighing the appointment of a new president for its metabolic franchise and a collaboration with China National Pharmaceutical Group.

See our latest analysis for HBM Holdings.

At a share price of HK$14.19, HBM Holdings has seen strong recent momentum, with a 21.8% 1 month share price return and a 17.5% year to date share price return, while the 3 year total shareholder return of about 7x suggests earlier investors have already seen very large gains.

If this kind of biotech news and price action has your attention, it can be useful to widen your watchlist by checking a focused list of 130 healthcare AI stocks

Given HBM Holdings' sharp recent gains and a share price still below the reference analyst target, the key issue now is whether most of the upside is already in the rearview mirror or whether valuation still leaves room for further appreciation.

Preferred P/E of 17.2x for HBM Holdings: Is it justified?

On a simple snapshot, HBM Holdings trades on a P/E of 17.2x, which sits below several benchmarks even after the recent share price strength.

The P/E ratio compares the current share price to earnings per share. For a biopharmaceutical company like HBM Holdings, it reflects how the market prices its current profitability while factoring in expectations for future earnings and the risk profile of drug development.

HBM Holdings has moved from losses to profitability over the past five years, with earnings growth described as very large in the latest year and a current net profit margin of 57.8%. At the same time, earnings are forecast to decline by about 4.9% per year over the next three years and the company’s Return on Equity is expected to be lower in three years than it is today. That mix of very strong historic earnings growth, high recent profitability and an earnings decline forecast helps explain why the current P/E of 17.2x looks higher than the company’s own estimated fair P/E of 11.8x.

Relative comparisons are also important here. HBM Holdings trades on a P/E of 17.2x compared with 25.1x for the Hong Kong Biotechs industry and 31.4x for the broader Asian Biotechs industry, and slightly below a peer average of 18.4x. That suggests the market is pricing HBM Holdings at a discount to many biotech peers, yet still at a premium to the 11.8x level that regression based fair ratio work points to as a possible destination if sentiment or growth expectations cool from here.

Explore the SWS fair ratio for HBM Holdings

Result: Price-to-Earnings of 17.2x (OVERVALUED).

However, the current revenue growth of 6.1% alongside declining annual net income growth and a value score of 2 may challenge the bullish case for HBM Holdings.

Find out about the key risks to this HBM Holdings narrative.

Another view on HBM Holdings using the SWS DCF model

The earlier P/E discussion suggested HBM Holdings trades at a premium to its fair ratio, despite sitting below many biotech peers. The SWS DCF model provides a different angle. At HK$14.19, the stock trades above an estimated fair value of about HK$8.94, which points to a materially overvalued picture on this cash flow based view. That gap could matter if sentiment cools and investors focus more on cash generation than headline earnings.

Our DCF model can be a useful cross check against headline multiples when you assess your own expectations for HBM Holdings. Look into how the SWS DCF model arrives at its fair value.

2142 Discounted Cash Flow as at Aug 2026
2142 Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 263 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing both optimism and concern around HBM Holdings, it makes sense to review the numbers yourself and decide how compelling the setup really looks. To weigh that mix of potential rewards and flagged risks side by side, start with the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond HBM Holdings?

To round out your view beyond HBM Holdings, it helps to line up a few fresh ideas so you are not relying on a single stock story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.